Goldman Sachs Lifts Price Target On Alexion Pharmaceuticals (ALXN)
Tweet
Share
E-mailGet Alerts ALXN Hot Sheet
Price: $182.01 --0%
Rating Summary:
10 Buy, 25 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 4 | Down: 9 | New: 31
Rating Summary:
10 Buy, 25 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 4 | Down: 9 | New: 31
Join SI Premium – FREE
Earlier, Goldman Sachs raised its price target on Buy-rated Alexion Pharmaceuticals (NASDAQ: ALXN) from $68 to $72 after the company received FDA approval and a positive CHMPopinion for approval of Soliris in aHUS for both adults and pediatrics.
For more ratings news on Alexion Pharmaceuticals click here and for the rating history of Alexion Pharmaceuticals click here.
Shares of Alexion Pharmaceuticals closed at $66.15 yesterday.
For more ratings news on Alexion Pharmaceuticals click here and for the rating history of Alexion Pharmaceuticals click here.
Shares of Alexion Pharmaceuticals closed at $66.15 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wedbush Downgrades Tscan Therapeutics Inc (TCRX) to Neutral
- Credo Tech (CRDO) PT Lowered to $310 at JPMorgan, Overweight Rating Maintained
- Palo Alto Networks (PANW) PT Raised to $420 at DA Davidson on Strong Q4 Upside
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Goldman SachsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
